6 completed, 1 recruiting, 1 terminated. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 6, Recruiting 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Yellow Fever: new trials by email Literature Review of Yellow Fever trials Research Report on Yellow Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for the Prevention of Yellow Fever, and of an Investigational Vaccine for the Prevention of Rabies, in Healthy Adults AVX70120 low dose level, AVX70120 middle dose level, AVX70120 high dose level - Yellow Fever, Rabies | Phase 1 | Completed | AstriVax Therapeutics | 112 | 2024-06-16 | 2026-04-22 |
| Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination 17D - Yellow Fever, Immunization; Infection | Phase 1 / Phase 2 | Recruiting | Oregon Health and Science University | 35 | 2023-08-01 | 2025-07-31 |
| Trial of an Inactivated Yellow Fever Virus Vaccine HydroVax-002 YFV, Placebo - Yellow Fever | Phase 1 | Completed | Najit Technologies, Inc. | 26 | 2022-01-13 | 2025-09-18 |
| The Effect of Inflammation and Damage to Lymph Node Structures on Durable Protective Immunity Following Yellow Fever Vaccination Yellow Fever Vaccine - Yellow Fever | Phase 1 / Phase 2 | Completed | University of Minnesota | 43 | 2020-07-01 | 2025-10-07 |
| A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 Galidesivir, Placebo - COVID-19, Yellow Fever | Phase 1 | Terminated | BioCryst Pharmaceuticals | 24 | 2020-04-09 | 2021-05-27 |
| Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults Yellow fever vaccine (produced on serum-free Vero cells), Dosage 1 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 2 vYF vaccine, Yellow fever vaccine (produced on serum-free Vero cells), Dosage 3 vYF vaccine - Yellow Fever (Healthy Volunteers) | Phase 1 | Completed | Sanofi Pasteur, a Sanofi Company | 73 | 2020-01-15 | 2025-09-22 |
| A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine - Yellow Fever, Yellow Fever Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 92 | 2016-07-05 | 2026-02-09 |
| Trial of Yellow Fever Inactivated Vaccine XRX-001 Inactivated yellow fever vaccine, Placebo - Yellow Fever | Phase 1 | Completed | GE Healthcare | 60 | 2010-01-01 | 2016-05-05 |
COVID-19 (1) · Fever (1) · Infections (1) · Rabies (1)
Arbovirus Infections (8) · Flaviviridae Infections (8) · Flavivirus Infections (8) · Hemorrhagic Fevers, Viral (8) · Mosquito-Borne Diseases (8) · RNA Virus Infections (8) · Vector Borne Diseases (8) · Virus Diseases (8) · Infections (7) · Body Temperature Changes (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Lung Diseases (1) · Mononegavirales Infections (1) · Nidovirales Infections (1)
Yellow Fever Vaccine (2) · Floors and Floorcoverings (1) · galidesivir (1) · smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic (1)
AstriVax Therapeutics (1) · BioCryst Pharmaceuticals (1) · GE Healthcare (1) · Najit Technologies, Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Oregon Health and Science University (1) · Sanofi Pasteur, a Sanofi Company (1) · University of Minnesota (1)
United States (6) · Belgium (1) · Brazil (1) · Uganda (1)
Amanada Culliton (1) · Christopher W Woods, MD, MPH (1) · Emmanuel B Walter, MD, MPH (1) · Esper Kallas, MD, PhD (1) · Timothy Schacker, MD (1) · William Messer, MD PhD (1)
272201300017C-18-0-1 (1), U01AI141981 (1), U44AI145791 (1)